Nippon Shinyaku Co., Ltd. · TSE:4516
Nippon Shinyaku — Investor Presentation (March 2026)
6 slides from Nippon Shinyaku's investor presentation, Mar 2, 2026
Slide 1: FY2025 Investor Meeting
FY2025 Investor Meeting March 2, 2026 Nippon Shinyaku Co., Ltd.
Slide 2: Agenda
Agenda Introduction 01 Toru Nakai Representative Director, President 02 Q&A 2
Slide 3: FY2025 R&D Milestones to Date
FY2025 R&D Milestones to Date 2025 Apr ✓ FDA granted Orphan Drug Designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis Jun ✓ Strategic alliance with Boston Children's Hospital for developing and delivering innovative therapies for rare diseases Sep ✓ FDA granted Fa
Slide 4: Overview of the 7th Medium-Term Management Plan - For Global Growth Beyond the Cliff
Overview of the 7th Medium-Term Management Plan - For Global Growth Beyond the Cliff - From May 27, 2024 The 7th Five-Year Medium-Term Management Plan, p.19 During the 7th Medium-Term Management Plan, we will promote "three key themes and strengthening five management foundations" to realize Vision
Slide 5: Our Target for New Product Launch
Our Target for New Product Launch Modified from May 8, 2025 FY2024 Financial Results, p.16 1. New indication We have been aiming to launch at least 2 new products each fiscal year 2. Newly added 3. Schedule delayed Period of the 7th Five-Year Medium-Term Management Plan Period of Next MT Plan FY2024
Slide 6: Safe Harbor Statement
Safe Harbor Statement • Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu